Abstract
To investigate the therapeutic effect of androgen on hypogonadal patients unresponsive to sildenafil alone. In total, 32 hypogonadal patients with erectile dysfunction (ED), initially had an inadequate response to sildenafil (100 mg). Oral testosterone undecanoate (Restandol®, 80 mg, bid or tid) alone was supplied for 2 months, and if patients could not achieve a satisfactory erection, combined use of testosterone and sildenafil was continued thereafter. Total testosterone (TT), free testosterone (FT), and the parameters of the International Index of Erectile Function (IIEF), International Prostate Symptom Score (IPSS), and uroflow rate (UFR) were assessed. Eleven patients (34.3%) achieved satisfactory erectile function after testosterone replacement only. Another 12 (37.5%) patients experienced satisfactory intercourse after combined therapy. Serum TT and FT levels significantly increased after the use of testosterone alone (415±163 vs 220±101 ng/dl, P<0.01; 10.4±4.6 vs 5.1±1.9 ng/dl; P<0.01, respectively) and the combined use of testosterone and sildenafil (498±178 vs 220±101 ng/dl, P<0.01; 11.7±4.6 vs 5.1±1.9 ng/dl, P<0.001, respectively); as did the IIEF score (14.8±6.8 vs 12.6±7.5, P<0.01, 17.5±5.2 vs 12.6±7.5, P<0.001, respectively). However, no statistical differences were demonstrated for IPSS or UFR. In conclusions, one-third of hypogonadal patients with ED who failed to respond to sildenafil, responded to testosterone alone, another third responded to sildenafil again after normalization of testosterone. So, in hypogonadal patients with ED, androgen supplementation is first-line therapy. If patients are unresponsive to androgen alone or sildenafil alone, combined use may improve erectile function and enhance the therapeutic effect of PDE-5 inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397–1404.
Nickel JC, Morales A, Condra M, Fenemore J, Surridge DH . Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. J Urol 1984; 132: 40–43.
Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol 2000; 53: 517–522.
Park K, Kim SW, Kim KD, Paick JS . Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999; 83: 327–333.
Ding AQ, Stallone JN . Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol 2001; 91: 2742–2750.
Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I . Effects of castration and androgen replacement on erectile function in a rabbit mode. Endocrinology 1999; 140: 1861–1868.
Lin C, Chow S, Lau A, Tu R, Lue TF . Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp-1 binding site. Biochem Biophys Res Comm 2001; 280: 693–699.
Vermeulen A . Androgen replacement therapy in the aging male – a critical evaluation. J Clin Endocrinol Metab 2001; 86: 2380–2387.
Shabsigh R, Kaufman JM, SteidLe C, Padma-Nathan H . Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–663.
Anderson RA, Bancroft J, Wu FC . The effects of exogenous testosterone on sexuality and mood of normal men. Clin Endocrinol Metab 1992; 75: 1503–1507.
Aversa A, Isidorit AM, Spera G, Lenzi A, Fabbri A . Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003; 58: 632–638.
Jockenhovel F . Testosterone therapy: what, when, and to whom. Aging Male 2004; 7: 319–324.
Guay AT, Bansal S, Heatley GJ . Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double-blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995; 80: 3546–3552.
Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A . Role of androgens in erection function. J Urol 2004; 171: 2358–2362.
Bhasin S, Bagatel CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998; 83: 3435–3448.
Gooren LJ . Endocrine aspects of ageing in the male. Mol Cell Endocrinol 1998; 145: 153–159.
Lugg JA, Rajfer J, Gonzalez-Cadavid NF . Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995; 136: 1495–1501.
Rajasekaran M, Mondal D, Agrawal K, Chen I, Hellstrom W, Sikka S . Ex vivo expression of nitric oxide synthase isoforms (eNOS/iNOS) and calmodulin in human penile cavernosal cells. J Urol 1998; 160: 2210–2214.
Janini EA, Screponi E, Carosa E, Pepe M, Logiudice F, Trimarch F et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999; 22: 385–392.
Acknowledgements
We thank Dr Paul C Chang for reviewing of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hwang, TS., Chen, HE., Tsai, TF. et al. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 18, 400–404 (2006). https://doi.org/10.1038/sj.ijir.3901446
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901446
Keywords
This article is cited by
-
The role of testosterone in male sexual function
Reviews in Endocrine and Metabolic Disorders (2022)
-
What are the benefits and harms of testosterone therapy for male sexual dysfunction?—a systematic review
International Journal of Impotence Research (2019)
-
Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails
Drugs & Aging (2018)
-
The Evaluation and Management of Testosterone Deficiency: the New Frontier in Urology and Men’s Health
Current Urology Reports (2013)